Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 299

Sort by

Sort Order Select

Journal Articles

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2025-5153

Published: 2025

Journal Articles

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Blood (2025) 146 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2025-2838

Published: 2025

Journal Articles

Trial in progress: nutrition and exercise to optimize muscle and adiposity in adolescents and young adults with B-cell acute lymphocytic leukemia: The neoma ALL trial

Samuel Yates, Lauren Miller, Suzanne Massarani, John Cursio, Nicholas Feinberg, Cassandra Kuissi, Karteek Popuri, Mirza Faisal Beg, Varun Akella, Brandon Faubert, Wendy Stock

Blood (2025) 146 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2025-1581

Published: 2025

Journal Articles

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Anand Patel, Theodore Karrison, Emily Dworkin, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Caner Saygin, Mariam Nawas, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Wendy Stock, Richard Larson, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2025-5608

Published: 2025

Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood (2025) 146 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2025-5954

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

Satoshi Yoshimura, Yizhen Li, Xu Yang, Christian Meyer, Guoqing Du, Yu-Chih Hsiao, Zhenhua Li, Wenjian Yang, Courtney Andersen, Caner Saygin, Seth Karol, Kathrin Bernt, Jiyang Yu, Wendy Stock, David Teachey, Marina Konopleva, Jun J. Yang

Blood (2025) 146 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2025-5081

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Hannah Johnston, Abigail Sneider, Tuula Pera, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Mariam Nawas, Anand Patel, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Olatoyosi Odenike, Richard Larson, Caner Saygin, Wendy Stock, Christopher Daugherty

Blood (2025) 146 (Supplement 1): 6382.

https://doi.org/10.1182/blood-2025-6382

Published: 2025

Journal Articles

A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl

Hoda Pourhassan, Jianying Zhang, Wendy Stock, Mark Geyer, Anjali Advani, Jae Park, Emily Curran, Katrin Tiemann, Vaibhav Agrawal, Paul Koller, Jose Tinajero, Tibor Kovacsovics, Anthony Selwyn Stein, Guido Marcucci, Melisa Stricherz, Stefan Faderl, Vinod Pullarkat, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 8233.

https://doi.org/10.1182/blood-2025-8233

Published: 2025

Journal Articles

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Blood (2025) 146 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2025-1590

Published: 2025

Journal Articles

Prospective analysis and clinical implications of therapy-related clonal hematopoiesis in adolescent and young adult survivors of acute lymphoblastic leukemia

Habib El-Khoury, Ella Postich, Diren Arda Karaoglu, Aishwarya Atmakuri, Hamed Rahmani Youshalouei, Adam Duvall, Wendy Stock, Tara Henderson, Caner Saygin

Blood (2025) 146 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2025-3319

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

Blood (2025) 146 (Supplement 1): 444.

https://doi.org/10.1182/blood-2025-444

Published: 2025

Journal Articles

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Blood (2025) 146 (Supplement 1): 441.

https://doi.org/10.1182/blood-2025-441

Published: 2025

Journal Articles

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Blood (2025) 146 (Supplement 1): 8183.

https://doi.org/10.1182/blood-2025-8183

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Trial in progress: nutrition and exercise to optimize muscle and adiposity in adolescents and young adults with B-cell acute lymphocytic leukemia: The neoma ALL trial

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Prospective analysis and clinical implications of therapy-related clonal hematopoiesis in adolescent and young adult survivors of acute lymphoblastic leukemia

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only